SANUWAVE, Inc. Health Submits to FDA First Module of PMA Application for dermaPACE for the Treatment of Diabetic Foot Ulcers  
12/10/2010 9:40:05 AM

ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTC BB: SNWV), an emerging medical technology company focused on regenerative medicine, today reported its submission to the U.S. Food and Drug Administration (FDA) of the first module of the Premarket Approval (PMA) application for the Company’s dermaPACE™ device for the treatment of diabetic foot ulcers (DFU).